Nov. 13 at 8:02 PM
$SNDX On Thursday, 13 November 2025, Syndax Pharmaceuticals (NASDAQ:SNDX) presented at the Stifel 2025 Healthcare Conference, highlighting both achievements and future ambitions. The company has seen significant progress with its oncology drugs, Revuforj and Niktimvo, while also preparing for further market expansion. With a robust financial position, Syndax aims to enhance its presence in the oncology sector.
Key Takeaways
Syndax secured three drug approvals last year, focusing on oncology.
Revuforj and Niktimvo are poised for expansion into earlier treatment lines.
The company maintains a strong financial position with
$456 million in cash.
Revuforj’s first-year performance is robust, with nearly full formulary coverage.
Niktimvo achieved profitability in its first full quarter post-launch.
Financial Results
Syndax Pharmaceuticals reported a solid financial foundation, with
$456 million in cash as of the last quarter.
